Ligand Pharmaceuticals (LGND) has been drawing attention after recent share performance data highlighted mixed short term returns alongside stronger longer term outcomes, prompting investors to reassess how its current pricing lines up with fundamentals.

At a share price of $199.62, Ligand Pharmaceuticals has seen short term share price pressure, with a 7 day return of 2.41% and a 30 day return of 1.45%. Longer horizons show stronger momentum, including a 90 day share price return of 5.58% and a 1 year total shareholder return of 83.59% that extends to 180.68% over three years.

If this kind of run has you thinking about what else could be setting up for strong multi year gains, it is worth scanning 20 top founder-led companies

With Ligand trading at $199.62 and indications of a discount to both analyst targets and intrinsic value, the key question is simple: is this still a genuine opportunity, or is the market already pricing in the future growth?

Most Popular Narrative: 18.4% Undervalued

With Ligand Pharmaceuticals last closing at $199.62 and the most followed narrative pointing to a fair value of $244.50, the current gap is all about whether future cash flows justify that higher figure.

Strong revenue and earnings growth are expected as Ligand broadens its high-margin royalty portfolio, with multiple partnered drugs (such as O2vir, Filspari, Qarziba, and Zelsuvmi) in various stages of commercialization or late-stage development. This expanding royalty base enhances recurring revenue, earnings visibility, and long-term cash flow predictability.

Want the full story behind that cash flow argument, including how growth, margins, and future earnings multiples fit together? The core of this narrative leans on compounding royalty streams, shifting profit margins, and a valuation multiple that assumes meaningful earnings power several years out. Curious which assumptions carry the most weight in reaching that $244.50 figure and how sensitive they are to different outcomes?

Result: Fair Value of $244.50 (UNDERVALUED)

However, this hinges on concentrated royalty assets and optimistic QTORIN assumptions. Regulatory setbacks or weaker partner execution could quickly challenge that undervalued story.

Another Way To Look At Valuation

The DCF work suggests Ligand is trading about 28.5% below an estimated fair value of $279.18, which supports the undervalued narrative built around future cash flows. The key question for you is whether those long term royalty and QTORIN assumptions feel robust enough to rely on.

Next Steps

If the mixed signals around value and growth leave you undecided, this may be a reasonable moment to review the numbers yourself, weigh the optimism, and see how 4 key rewards

Ready for more investment ideas?

If Ligand has sharpened your thinking, do not stop here; broaden your watchlist with curated stock ideas that match what you want from your portfolio.

• Target stability first by reviewing companies in the 65 resilient stocks with low risk scores that may suit a more cautious approach.
• Hunt for potential mispricing by scanning the 63 high quality undervalued stocks for businesses where fundamentals and price look out of sync.
• Spot opportunities with solid footing by checking the solid balance sheet and fundamentals stocks screener (39 results) if you care about resilient financial positions.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.